公开(公告)号：WO2014170487A1

公开(公告)日：2014-10-23

申请号：PCT/EP2014/058021

申请日：2014-04-18

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE PARIS DESCARTES ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： BAUD, Véronique ,  BILLOT, Katy

IPC: G01N33/50

CPC classification number: G01N33/6872 ,  C07K16/18 ,  G01N33/57484 ,  G01N2333/4703 ,  G01N2440/14 ,  G01N2500/04 ,  G01N2500/10

Abstract: The present Inventors demonstrated that the RelB subunit of NFκB plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the NFκB pathway through RelB phosphorylationat serine 472. In a first aspect, the present invention proposes to monitor the activation of the NFκB pathway by following the phosphorylation status of said serine. Also, the present invention discloses methods and kits for prognosing the evolution of a disease involving cell migrationin a subject –treated or not -suffering thereof, based on the detection of said RelB-S472 phosphorylation.

Abstract translation: 本发明人证明，NF＆KgrB的RelB亚基在促进细胞迁移中起关键作用。 更准确地说，他们认为这种迁移前的活性是通过通过RelB磷酸化丝氨酸472激活NF＆kgr B途径来介导的。在第一方面，本发明提出通过以下方法监测NF＆kgr B途径的活化 所述丝氨酸的磷酸化状态。 此外，本发明公开了用于根据所述RelB-S472磷酸化的检测来预测涉及受试者或未被治疗的受试者的细胞迁移的疾病进展的方法和试剂盒。

公开(公告)号：WO2014124953A1

公开(公告)日：2014-08-21

申请号：PCT/EP2014/052700

申请日：2014-02-12

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ,  UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES

Inventor： ORLIKOWSKI, David

IPC: A61M16/04

CPC classification number: A61M16/0493 ,  A61M16/0418

Abstract: A noninvasive ventilation mouthpiece (10) comprises a first end, provided with connection means (12) for connecting the mouthpiece to a gas supply system (20), a second end (14), to be placed in a patient's mouth during use of the mouthpiece, and a tubular body (16) joining the first and second ends. The tubular body (16) includes at least a flexible portion and the second end (14) is adjustable in one or several directions (F1, F2) with respect to the first end (12), via bending of the flexible portion.

Abstract translation: 非侵入性通气口件（10）包括第一端，设置有用于将吸嘴连接到气体供应系统（20）的连接装置（12），第二端（14），以在使用期间放置在患者的口中 接口和连接第一和第二端的管状体（16）。 管状体（16）至少包括柔性部分，并且第二端部（14）可相对于第一端部（12）在一个或多个方向（F1，F2）上通过柔性部分的弯曲而可调节。

公开(公告)号：WO2014083018A1

公开(公告)日：2014-06-05

申请号：PCT/EP2013/074790

申请日：2013-11-26

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) ,  UNIVERSITÉ DE STRASBOURG

Inventor： GRONEMEYER, Hinrich ,  MENDOZA PARRA, Marco Antonio

IPC: G06F19/22 ,  G06F19/24

CPC classification number: G06F19/22 ,  G06F17/30371 ,  G06F19/24

Abstract: This method for processing data for evaluating a quality level of an original dataset resulting from an automated sequencing of a chain of nucleotides, wherein said sequenced chain comprises a plurality of predefined identified regions and said original dataset represents a plurality of total mapped reads, comprises - sampling (32) of the plurality of total mapped reads of said original dataset to produce a subset comprising a plurality of sampled mapped reads; - for each said data subset, computing (34) a dispersion indicator for each identified region, representative the divergence between an actual read count intensity and a theoretical read count intensity, the actual read count corresponding to the number of sampled mapped reads in this identified region, the theoretical read count corresponding to a theoretical number of sampled mapped which does not depend on the current sampling.

Abstract translation: 用于处理用于评估由核苷酸链的自动测序产生的原始数据集的质量水平的数据的方法，其中所述测序链包括多个预定义的识别区域，并且所述原始数据集表示多个总映射读取， 对所述原始数据集的多个总映射读取中的采样（32）以产生包括多个采样映射读取的子集; - 对于每个所述数据子集，计算（34）每个识别的区域的色散指示符，代表实际读取计数强度和理论读取计数强度之间的差异，所述实际读取计数对应于在该识别的所述数据子集中的采样映射读取的数量 区域，对应于不依赖于当前采样的采样映射的理论数量的理论读数。

公开(公告)号：WO2014044853A8

公开(公告)日：2014-03-27

申请号：PCT/EP2013/069751

申请日：2013-09-23

Applicant: INTEGRAGEN ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE PARIS DESCARTES

Inventor： DE REYNIES, Aurélien ,  LAURENT-PUIG, Pierre ,  ZUCMAN-ROSSI, Jessica ,  NAULT, Jean-Charles

IPC: C12Q1/68

Abstract: The present invention relates to the technical field of liver diseases, their classification and diagnosis. It provides a new method for classifying a liver sample between non- hepatocellular sample; hepatocellular carcinoma (HCC) sample with further classification into one of subgroups G1 to G6; focal nodule dysplasia (FNH) sample; hepatocellular adenoma (HCA) sample with further classification into HNF1A mutated HCA, inflammatory HCA, β catenin mutated HCA or other HCA sample; and other benign liver sample, based on determination in vitro of genes expression profiles and analysis of the expression profile using algorithms calibrated with reference samples. The invention also provides kits for the classification of liver samples, and methods of treatment of liver disease in a subject based on a preliminary classification of a liver sample of said subject.

公开(公告)号：WO2014001562A1

公开(公告)日：2014-01-03

申请号：PCT/EP2013/063791

申请日：2013-07-01

Applicant: CENTRE LEON BERARD ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE CLAUDE BERNARD LYON 1

Inventor： TREILLEUX, Isabelle ,  BACHELOT, Thomas ,  LE ROMANCER-CHERIFI, Muriel

IPC: A61K31/436 ,  A61P35/00

CPC classification number: A61K31/436 ,  A61K31/138 ,  G01N33/57415 ,  G01N2333/912

Abstract: Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB1 gene in a breast tumour sample previously taken from a breast cancer patient, Classifying the breast cancer as likely to respond to treatment with everolimus if the LKB1 gene is under- expressed in said breast tumour sample.

Abstract translation: 用于鉴定可能对依维莫司治疗有反应的乳腺癌的方法，包括以下步骤：测量先前从乳腺癌患者获得的乳腺肿瘤样品中的LKB1基因的表达水平，将乳腺癌分类为可能对治疗作出反应 如果LKB1基因在所述乳腺肿瘤样品中低表达，则具有依维莫司。

公开(公告)号：WO2013160492A1

公开(公告)日：2013-10-31

申请号：PCT/ES2012/070276

申请日：2012-04-24

Applicant: FUNDACIÓN INSTITUTO MEDITERRÁNEO PARA EL AVANCE DE LA BIOTECNOLOGÍA Y LA INVESTIGACIÓN SANITARIA (IMABIS) ,  VIVIABIOTECH, S.L. ,  UNIVERSIDADE DE SANTIAGO DE COMPOSTELA ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  JOHANNES GUTENBERG UNIVERSITAET MAINZ ,  ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA ,  RODRÍGUEZ DE FONSECA, Fernando Antonio ,  RIVERA GONZÁLEZ, Patricia ,  SUÁREZ PÉREZ, Juan ,  BALLESTEROS NOBELL, Juan ,  DIÉGUEZ GONZÁLEZ, Carlos ,  NOGUEIRAS POZO, Rubén ,  MARSICANO, Giovanni ,  PAGOTTO, Uberto ,  LUTZ, Beat

Inventor： RODRÍGUEZ DE FONSECA, Fernando Antonio ,  RIVERA GONZÁLEZ, Patricia ,  SUÁREZ PÉREZ, Juan ,  BALLESTEROS NOBELL, Juan ,  DIÉGUEZ GONZÁLEZ, Carlos ,  NOGUEIRAS POZO, Rubén ,  MARSICANO, Giovanni ,  PAGOTTO, Uberto ,  LUTZ, Beat

IPC: A61K31/36 ,  A61K31/164 ,  A61K38/26 ,  A61P3/04

CPC classification number: A61K31/164 ,  A61K31/335 ,  A61K31/36 ,  A61K38/26 ,  A61K2300/00

Abstract: La invención se relaciona con el uso de agonistas del receptor beta-3 adrenérgico en una terapia combinada para el tratamiento de enfermedades metabólicas como hiperglicemias, resistencia a la insulina, diabetes tipo 2 y dislipidemias. En dicha terapia se combina la administración de un agonista del receptor beta-3 adrenérgico con un agonista del receptor de GLP-1 o un agonista de PPARα, ambos compuestos capaces de reducir el apetito, reducir el incremento de peso e incrementar el gasto energético mediante la movilización de la grasa. La presente invención muestra que la administración combinada de dichos compuestos presenta un efecto sinérgico enla reducción de la grasa corporal.

Abstract translation: 本发明涉及β-3肾上腺素能受体激动剂在联合治疗中用于治疗代谢性疾病如高血糖症，胰岛素抵抗，2型糖尿病和血脂异常的用途。 该疗法结合了β-3肾上腺素能受体激动剂与GLP-1受体激动剂或PPARα激动剂的给药，两种化合物都能够通过脂肪动员降低食欲，减轻体重增加和增加能量消耗。 本发明表明，所述化合物的组合给药对身体脂肪的减少具有协同作用。

公开(公告)号：WO2013128022A1

公开(公告)日：2013-09-06

申请号：PCT/EP2013/054218

申请日：2013-03-01

Applicant: UNIVERSITÉ DE STRASBOURG ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： ROBINET, Eric ,  BAUMERT, Thomas

IPC: A61K48/00 ,  A61P31/20 ,  C12N5/0783 ,  A61P31/14 ,  A61K35/14

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K48/0008 ,  A61K48/0075 ,  C07K2319/40 ,  C12N9/1211 ,  C12N2501/2302 ,  C12N2501/515 ,  C12N2510/00 ,  C12N2799/027

Abstract: The present invention relates to the prevention of liver graft infection by HCV and/or HBV in a patient infected by HCV and/or HBV in need of liver transplantation, and to the treatment of a patient chronically infected by HCV and/or HBV. More specifically, this invention relates to allogeneic lymphocytes expressing a "suicide gene" to prevent infection by HCV and/or HBV of a liver graft and to treat a patient chronically infected by HCV and/or HBV. The invention also concerns a lymphocyte bank comprising a plurality of allogeneic lymphocytes expressing a "suicide gene".

Abstract translation: 本发明涉及在需要肝移植的HCV和/或HBV感染的患者中预防HCV和/或HBV的肝移植物感染，以及对HCV和/或HBV长期感染的患者的治疗。 更具体地，本发明涉及表达“自杀基因”的同种异体淋巴细胞，以防止肝移植物的HCV和/或HBV感染并治疗长期被HCV和/或HBV感染的患者。 本发明还涉及包含表达“自杀基因”的多个同种异体淋巴细胞的淋巴细胞库。

公开(公告)号：WO2013110790A1

公开(公告)日：2013-08-01

申请号：PCT/EP2013/051503

申请日：2013-01-25

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE PARIS DESCARTES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7

Inventor： BOMSEL, Morgane ,  TUDOR, Daniela

IPC: C07K7/08 ,  C07K16/10 ,  A61K39/395 ,  C07K14/16

CPC classification number: A61K39/21 ,  A61K39/12 ,  A61K2039/507 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/55522 ,  C07K16/1063 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/92 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2795/14143

Abstract: Novel antibodies and peptides relating to HIV are disclosed, as are vaccine compositions containing such antibodies and peptides. The compounds and compositions of the invention are of use in prevention and treatment of HIV, and in particular for inducing mucosal immunity to HIV.

Abstract translation: 公开了与HIV相关的新型抗体和肽，以及含有这种抗体和肽的疫苗组合物。 本发明的化合物和组合物可用于预防和治疗HIV，特别是用于诱导对HIV的粘膜免疫。

公开(公告)号：WO2013092412A1

公开(公告)日：2013-06-27

申请号：PCT/EP2012/075554

申请日：2012-12-14

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： LEVY, Yves

IPC: G01N33/68

CPC classification number: G01N33/6866 ,  G01N33/6869 ,  G01N2333/7155 ,  G01N2800/32

Abstract: The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

Abstract translation: 本发明涉及关于IL-1受体家族蛋白ST2的材料和方法。 提供了可溶性ST2作为心血管疾病或疾病预后指标的使用，特别是作为死亡风险的标志物。

公开(公告)号：WO2013076282A1

公开(公告)日：2013-05-30

申请号：PCT/EP2012/073535

申请日：2012-11-23

Applicant: INTEGRAGEN ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： RIO FRIO, Thomas ,  LAURENT-PUIG, Pierre ,  IMBEAUD, Sandrine

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.

Abstract translation: 本发明涉及一种预测癌症患者是否可能对表皮生长因子受体（EGFR）抑制剂作出反应的方法，该方法包括测定所述癌细胞样品中hsa-miR-31-3p miRNA的表达水平 患者。 本发明还涉及预测对所述EGFR抑制剂作出反应的患者中EGFR抑制剂的治疗用途。